Latest Conference Articles

Data from the phase 2 NIFTY trial demonstrated that a combination with liposomal irinotecan significantly improved survival in patients with metastatic biliary tract cancer.

Looking at 6.5 years of follow-up data from the phase 3 CheckMate-067 trial shows maintained outcomes in patients with advanced melanoma on nivolumab alone, or with ipilimumab.

Further follow up of lifileucel in patients with melanoma showed potentially follow progression on anti—PD-1 therapy.

Pediatric patients with advanced RET-altered solid tumors showed preliminary efficacy with selpercatinib, according to data presented at the 2021 ASCO Annual Meeting.

Updated findings show how selpercatinib improves responses in patients with RET-mutant medullary thyroid cancer regardless of the prior treatment they had.

Patients with early-stage breast cancer who have ultralow risk disease, indicated by a 70-gene signature, demonstrated an excellent survival prognosis regardless of clinical risk.

New data from the phase 3 IMPACT trial shows the advantages and shortcomings of gefitinib in patients with EGFR-mutant non-small cell lung cancer.

Results from phase 1 data looking at CART-ddBCMA show a 100% objective response rate among patients with relapsed/refractory multiple myeloma.

In an updated analysis of the combination of lenvatinib and pembrolizumab for patients with advanced melanoma, efficacy results continue to show a durable response.

Results from a phase 2 trial of patients with HER2-positive breast comparing TCbH alone and TCbH with pyrotinib showed significant improvement when adding pyrotinib, according to data presented at ASCO.

Utilizing a de-escalation of treatment strategy, researchers found a high response and significant results among patients with HER2+ breast cancer.

Pertuzumab, trastuzumab, and nab-paclitaxel used as neoadjuvant therapy in patients with HER2-positive locally advanced breast cancer showed comparable pathologic complete response with docetaxel, carboplatin, trastuzumab, and pertuzumab with less toxicities.

Treatment-naïve patients with melanoma who crossed over to receive pembrolizumab had an ORR of 38.8% and a 3-year PFS of 32% according to updated data from the phase 3 EORTX 1325/KEYNOTE-054 trial.

The combination of tafasitamab-cxix and lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma showed sustainable responses at 3-year follow-up of the phase 2 L-MIND trial.

Alexander Spira, MD, PhD, FACP, director of the Virginia Cancer Specialists Research Institute, discusses the safety profile of amivantamab and lazertinib in EGFR-mutated non-small cell lung cancer, based on data from the CHRYSALIS tria.

Overall survival was maintained, and even improved, in patients with pretreated HER2-positive breast cancer receiving tucatinib plus trastuzumab and capecitabine versus placebo.

No clinical activity was elicited by selumetinib in pediatric and young adult patients with refractory cancers.

In patients with advanced or metastatic esophageal squamous cell carcinoma, Camrelizumab in combination with chemotherapy demonstrated improved overall survival and progression-free survival and a manageable safety profile as frontline therapy compared with placebo plus chemotherapy.

Overall survival in postmenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer at almost 5 years of follow-up continued to improve with Ribociclib plus fulvestrant over fulvestrant alone, irrespective of whether patients received the regimen in the first- or second-line setting.

Encouraging clinical and pharmacodynamic activity was seen at all dose levels in patients with B-cell malignancies who received TG-1701.

Consistent efficacy was seen with selpercatinib in patients with RET fusion-positive non-small cell lung cancer, regardless of prior treatments.

Promising responses rates were seen with larotrectinib, a highly selective, central nervous system-active TRK inhibitor, in patients with TRK fusion cancer, including in those with CNS metastases at baseline.

In an update of the ARROW trial, pralsetinib was well tolerated and demonstrated robust and durable anti-tumor activity in heavily pretreated patients with multiple RET fusion–positive advanced solid tumors.

Niraparib has an acceptable safety profile for patients with platinum-sensitive recurrent ovarian cancer, regardless of the dose being adjusted for weight, according to updated results from the phase 3 NORMA trial.

Based on 7-year follow-up data, the use of front-line ibrutinib monotherapy has sustained progression-free survival and overall survival benefit compared with chlorambucil as treatment of patients with chronic lymphocytic leukemia.

The novel agent, zenocutuzumab demonstrated promise as treatment of patients with NRG1 fusion–positive cancers, in the phase 1/2 eNRGy study.

Updated results from the phase 2 CodeBreaK100 trial were presented by Ferdinandos Skoulidis, MD, PhD during the 2021 ASCO Annual Meeting.

New data from the phase 2 SPEARHEAD-1 trial showed that afami-cel can elicit encouraging responses in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma.

Allogeneic hematopoietic cell transplantation was shown to be safe when performed with a reduced-intensity conditioning regimen of bortezomib, fludarabine, and melphalan in patients with high-risk multiple myeloma

A robust and durable response was seen in heavily pretreated patients with relapsed/refractory B-cell acute lymphoblastic leukemia after receiving a single infusion of KTE-X19, a CAR T-cell therapy.